Evaluation of guideline for treatment of febrile neutropenia in pediatric cancer at Siriraj Hospital

Journal of the Medical Association of Thailand

Volumn 88, Issue SUPPL. 8, 2005, Pages

  Sanpakit, Kleebsabai ^a   Phuakpet, Kamon ^a   Veerakul, Gavivann ^a   Narkbunnam, Nattee ^a   Chokephaibulkit, Kulkanya ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b NONE

Author keywords

Clinical Practice Guideline; Febrile neutropenia; Pediatric cancer

Indexed keywords

AMIKACIN; AMPHOTERICIN B; ANTIBIOTIC AGENT; CEFTAZIDIME; GENTAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMIPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM;

ACUTE LEUKEMIA; CAUSE OF DEATH; CHILD; CHILDHOOD CANCER; CHOLERA; CONTROLLED STUDY; DATA ANALYSIS; FEBRILE NEUTROPENIA; FEMALE; FUNGEMIA; GRAM NEGATIVE BACTERIUM; HEMATOLOGIC MALIGNANCY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICAL SPECIALIST; MORTALITY; NEUTROPHIL COUNT; PATIENT CARE; PRACTICE GUIDELINE; RECURRENT FEVER; REVIEW; RISK FACTOR; SEPSIS; URINARY TRACT INFECTION;

CHILD; CHILD, PRESCHOOL; FEMALE; FEVER; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, NONLYMPHOCYTIC, ACUTE; LEUKOCYTE COUNT; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; NEOPLASMS; NEUTROPENIA; NEUTROPHILS;

EID: 31744431607     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Pizzo PA. Fever in immunocompromised patients. N Engl J Med 1999;341:893-900.
2. Donowitz GR. Infections in the neutropenic patient: an overview. In: Schechter GP, Broudy VC, Williams ME, eds. Hematology 2001 American Society of Hematology Educational program book. Washington : Amgen Oncology, 2001:113-8.
3. Bodey GP, Bruckley M, Sathe YS, Freireich EJ. Quantitation relationships between circulating leukocytes and infection in patients with acute leuke-mia. Ann Int Med 1996;64:328-40.
4. Santolaya ME, Alwarez AM, Becker A, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia and fever. J Clin Oncol 2001;19:3415-21.
5. Pizzo PA, Rubin M, Freifeld A, Pizzo PA, Rubin M, Freifeld A, Walsh TJ. the child with cancer and infection: Empiric therapy for fever and neutropenia and preventive strategies. J Pediatr 1991;119:679-94.
6. Klastersky J. Febrile neutropenia. Curr Opin Oncol 1993;5:625-32.
7. Hodgson-Viden H, Grundy PE, Robinson JL. Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia. BMC Pediatrics 2005;5:10-6.
8. Hughes WT, Armstrong D, Bodey GP, Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS. 2002 guidelines for use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
9. st century. Cancer 2005; 103:1103-13.
10. Picazo JJ. Management of the febrile neutropenic patients: a consensus conference. Clin Infect Dis 2004;39:S1-6.
11. Bodey GP. Managing infections in the immuno-compromised patient. Clin Infect Dis 2005;40:S239.
12. Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 2004;39:S32-7.
13. Elting LS, Rubenstein EB, Rolston K, Elting LS, Rubenstein EB, Rolston K, Cantor SB, Martin CG, Kurtin D, Rodriguez S, Lam T, Kanesan K, Bodey G. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care. J Clin Oncol 2000;18:3699-706.
14. Rolston KVI. The infectious diseases society of Americe 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia : Salient features and comments. Clin Infect Dis 2004;39:S44-8.
15. Kern WV, Cometta A, Bock RD, Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Eng J Med 1999;341:312-8.
16. Perrone J, Hollander JE, Datner EM. Emergency department evaluation of patients with fever and chemotherapy induced neutropenia. J Emerg Med 2004;27:115-9.
17. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-32.
18. Woo PC, Wong SS, Lum PN, Hui W, Yuen K. Cell-wall-deficient bacteria and culture-negative febrile episodes in bone-marrow-transplant recipients. Lancet 2001;357:675-9.
19. Giamarellou H, Antoniadou A. Infectious complications of febrile leukopenia. Infect Dis Clin North Am 2001;15:457-82.
20. Kanamaru A, Tatsumi Y. Microbiological data from patients with febrile neutropenia. Clin Infect Dis 2004;39:S7-10.
21. Whimbey E, Englund JA, Couch RB. Community respiratory virus infections in immunocompromised patients with cancer. Am J Med 1997;102:10-8.
22. Clark OAC, Lyman GH, Castro AA, Clark LGO, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005;23:4198-214.
23. Lyman GH, Lyman CH, Agboola O, for the ANC study group. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005;10:427-37.
24. Rolston KVI, Rubenstein EB, Freifeld A. Early empiric antibiotic therapy for febrile neutropenia patients at low risk. Infect Dis Clin North Am 1996; 10:223-37.
25. Yoshida M, Ohno R. Antimicrobial prophylaxis in febrile neutropenia. Clin Infect Dis 2004;39:S65-7.
26. Peralta GS, Salzman CT, Garcia GJJ, Aquado EJ, Giralt GA, Cubells LC. Bacteremia risk criteria in the predictic febrile neutropenic cancer patient. Clin Transl Oncol 2005;7:165-8.